Statistical optimization of tetrahydrocurcumin loaded solid lipid nanoparticles using Box Behnken design in the management of streptozotocin-induced diabetes mellitus

• Published in: Saudi pharmaceutical journal Vol. 31; no. 9; p. 101727
• Main Authors: Bharti Sharma, Jai, Bhatt, Shailendra, Tiwari, Abhishek, Tiwari, Varsha, Kumar, Manish, Verma, Ravinder, Kaushik, Deepak, Virmani, Tarun, Kumar, Girish, Al kamaly, Omkulthom, Saleh, Asmaa, Khalid Parvez, Mohammed, Alhalmi, Abdulsalam
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.09.2023; Elsevier
• Subjects: Box-Behnken design; Original; Pharmacodynamic study; Pharmacokinetic study; SLN; STZ-induced Diabetes Mellitus; Tetrahydrocurcumin; STZ-induced Diabetes Mellitus; Pharmacokinetic study; SLN; Box-Behnken design; Pharmacodynamic study; Tetrahydrocurcumin
• ISSN: 1319-0164; 2213-7475
• DOI: 10.1016/j.jsps.2023.101727

In the past, curcumin was the go-to medication for diabetes, but recent studies have shown that tetrahydrocurcumin is more effective. The problem is that it's not very soluble in water or very bioavailable. So, our research aims to increase the bioavailability and anti-diabetic efficacy of tetrahydrocurcumin in streptozotocin-induced diabetic rats by synthesizing tetrahydrocurcumin-loaded solid lipid nanoparticles. Box Behnken Design was employed for the optimization of tetrahydrocurcumin-loaded solid lipid nanoparticles (THC-SLNs). The optimal formulation was determined by doing an ANOVA to examine the relationship between the independent variables (drug-to-lipid ratio, surfactant concentration, and co-surfactant concentration) and the dependent variables (particle size, percent entrapment efficiency, and PDI). Particle size, PDI, and entrapment efficiency all showed statistical significance based on F-values and p-values. The optimized batch was prepared using a drug-to-lipid ratio (1:4.16), 1.21% concentration of surfactant, and 0.4775% co-surfactant (observed with a particle size of 147.1 nm, 83.58 ± 0.838 % entrapment efficiency, and 0.265 PDI, and the values were found very close with the predicted ones. As the THC peak vanishes from the DSC thermogram of the improved formulation, this indicates that the drug has been transformed from its crystalline form into its amorphous state. TEM analysis of optimized formulation demonstrated mono-dispersed particles with an average particle size of 145 nm which are closely related to zetasizer’s results. In-vitro release study of optimized formulation demonstrated burst release followed by sustained release up to 71.04% throughout 24 hrs. Increased bioavailability of the adjusted THC-SLN was found in an in vivo pharmacokinetics research with 9.47 folds higher AUC(0-t) compared to plain THC-suspension. Additionally, pharmacodynamic experiments of optimized formulation demonstrated a marked decrease in blood glucose level to 63.7% and increased body weight from 195.8 ± 7.223 to 231.2 ± 7.653 on the 28th day of the study and showed a better anti-diabetic effect than plain drug suspension. Results of stability studies revealed that formulation can be stored for longer periods at room temperature. Tetrahydrocurcumin can be effectively administered by SLN for the treatment of diabetes.